How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/glucocorticoid-induced-osteoporosis.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-09 · How we verify

Glucocorticoid Induced Osteoporosis — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Glucocorticoid Induced Osteoporosis (disease) competitive landscape: 9 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

9 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Glucocorticoid Induced Osteoporosis, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Zometa	ZOLEDRONIC ACID	Novartis	zoledronic acid	Farnesyl pyrophosphate synthase	2001-01-01
Infuvite Adult	Colecalciferol	Novartis	Vitamin D	Vitamin D3 receptor	2000-01-01
Fosamax	ALENDRONIC ACID	Merck And Co Inc	Vitamin D [EPC]	Farnesyl pyrophosphate synthase	1995-01-01
Drisdol	ERGOCALCIFEROL	Esjay Pharma	Provitamin D2 Compound [EPC]	25-hydroxyvitamin D-1 alpha hydroxylase, mitochondrial	1941-01-01
Zoledronate	Zoledronate	Children's Hospital Medical Center, Cincinnati		Butyrophilin subfamily 3 member A1, 72 kDa type IV collagenase, Geranylgeranyl pyrophosphate synthase
alendronate	alendronate	Massachusetts General Hospital		Farnesyl pyrophosphate synthase, Farnesyl pyrophosphate synthase, Farnesyl pyrophosphate synthase, EC 2.5.1.1, EC 2.5.1.10
Risedronate	Risedronate	Toronto Rehabilitation Institute		Butyrophilin subfamily 3 member A1, Farnesyl pyrophosphate synthase, Farnesyl diphosphate synthase
Zometa	Zometa	University of Arkansas		Butyrophilin subfamily 3 member A1, 72 kDa type IV collagenase, Geranylgeranyl pyrophosphate synthase
Calciferol	Calciferol	Department of Medical Services Ministry of Public Health of Thailand		Vitamin D 25-hydroxylase, 25-hydroxyvitamin D-1 alpha hydroxylase, mitochondrial, Vitamin D3 receptor

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

Novartis · 2 drugs in Glucocorticoid Induced Osteoporosis
Children's Hospital Medical Center, Cincinnati · 1 drug in Glucocorticoid Induced Osteoporosis
Department of Medical Services Ministry of Public Health of Thailand · 1 drug in Glucocorticoid Induced Osteoporosis
Esjay Pharma · 1 drug in Glucocorticoid Induced Osteoporosis
Massachusetts General Hospital · 1 drug in Glucocorticoid Induced Osteoporosis
Merck And Co Inc · 1 drug in Glucocorticoid Induced Osteoporosis
Toronto Rehabilitation Institute · 1 drug in Glucocorticoid Induced Osteoporosis
· 1 drug in Glucocorticoid Induced Osteoporosis
University of Arkansas · 1 drug in Glucocorticoid Induced Osteoporosis

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Glucocorticoid Induced Osteoporosis:

Cite this brief

Drug Landscape (2026). Glucocorticoid Induced Osteoporosis — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/glucocorticoid-induced-osteoporosis. Accessed 2026-06-09.

Glucocorticoid Induced Osteoporosis full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing